Star Health Insurance
Star Health & Allied Insurance Company Ltd
- Market Cap
- ₹32,730 Cr
- P/E
- 31.05
Key Fundamentals
SmallcapInsuranceFinancial ServicesPrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 9.69%
- Debt to Equity
- 0.01
- EPS (TTM)
- ₹17.91
- Book Value
- ₹177.29
- Market Cap
- ₹32,730 Cr
- P/E (TTM)
- 31.05
- P/B
- 3.14
- ROE
- 7.61%
- Dividend Yield
- 0.00%
- EBITDA
- ₹834 Cr
- 52W High
- ₹624.90
- 52W Low
- ₹416.55
- Day Range
- ₹553.40 – ₹566.00
- Volume
- 2,64,371
Peer Comparison
Financial Services › Insurance › General Insurance
| 1,736.00 | 33.90 | 86,733 | 4.61 | 0.43% | 16.60% | 21.90% | 29,038 | 2,555 | |
| 332.30 | 6.50 | 58,299 | 0.79 | 3.91% | 14.60% | 17.40% | 54,993 | 8,969 | |
| 556.05 | 31.05 | 32,730 | 3.14 | 0.00% | 7.61% | 9.69% | 20,056 | 1,054 | |
| 152.63 | — | 25,153 | 0.89 | 1.00% | 4.92% | 4.29% | 50,234 | −528 | |
| 239.00 | 27.25 | 22,111 | 2.72 | 0.00% | 12.20% | 13.10% | 11,994 | 810 | |
| 74.36 | 39.76 | 13,754 | 3.58 | 0.00% | 3.46% | 3.15% | 8,905 | 345 | |
| Median 6 companies | 285.65 | 31.05 | 28,942 | 2.93 | 0.22% | 9.91% | 11.40% | 24,547 | 932 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 97/100
Category scores
- Quality
- 47
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 47
- Average
- Cheap vs sector & own history 24% weight
- Growth
- 50
- Average
- Sales & profit trajectory 9% weight
- Financial Health
- 33
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 62
- Good
- Trend strength, vol-adjusted 12% weight
- Ownership
- 34
- Poor
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company has reduced debt.
- Company is almost debt free.
Weaknesses
3- Stock is trading at 3.14 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.2% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 3 | 7 | 9 |
| Oscillators | Bullish | 0 | 7 | 2 |
| Moving Averages | Strong Bullish | 3 | 0 | 7 |
Oscillators
Bullish
Overall
Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 51.36
- Neutral
- MACD (12,26,9)
- 4.66
- Bullish
- SMA (50)
- 548.83
- Bullish
- SMA (200)
- 531.33
- Bullish
As of
Analyst Rating
16 of 18 analysts rate Buy, 1 Hold, 1 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +27.30% |
|---|---|
| 5Y | +28.69% |
| 3Y | +13.80% |
| 1Y | +10.71% |
| TTM | +13.51% |
Net profit
| 10Y | +15.06% |
|---|---|
| 5Y | Turned to profit |
| 3Y | −3.46% |
| 1Y | −13.78% |
| TTM | +43.60% |
Operating cash flow
| 10Y | — |
|---|---|
| 5Y | +16.05% |
| 3Y | +13.65% |
| 1Y | +35.82% |
| TTM | — |
10Y: The statements do not go back far enough for this window.
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −5.16 pp |
|---|---|
| 5Y | +32.28 pp |
| 3Y | −2.60 pp |
| 1Y | −1.10 pp |
| TTM | +1.58 pp |
Revenue by year
| Mar 2017 | ₹2,012 Cr |
|---|---|
| Mar 2018 | ₹2,888 Cr |
| Mar 2019 | ₹3,775 Cr |
| Mar 2020 | ₹4,987 Cr |
| Mar 2021 | ₹5,050 Cr |
| Mar 2022 | ₹10,602 Cr |
| Mar 2023 | ₹12,096 Cr |
| Mar 2024 | ₹14,021 Cr |
| Mar 2025 | ₹16,101 Cr |
| Mar 2026 | ₹17,825 Cr |
Net profit by year
| Mar 2017 | ₹118 Cr |
|---|---|
| Mar 2018 | ₹170 Cr |
| Mar 2019 | ₹128 Cr |
| Mar 2020 | ₹268 Cr |
| Mar 2021 | −₹1,086 Cr |
| Mar 2022 | −₹1,041 Cr |
| Mar 2023 | ₹619 Cr |
| Mar 2024 | ₹845 Cr |
| Mar 2025 | ₹646 Cr |
| Mar 2026 | ₹557 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Star Health & Allied Insurance, trading at ₹568.65 as of 2026-11-19 with a market cap of ₹33,472 Cr, is a virtually debt-free standalone health insurer that has delivered strong long-term sales growth of 27% CAGR over 10 years and a TTM profit growth of 44%, but trades at a P/E of 31.75x and P/B of 3.21x with no dividend payout and a modest ROE of 7.35%.
- TTM profit growth of 44% signals a sharp earnings recovery, suggesting improving underwriting discipline or favourable claims experience
- 10-year compounded sales growth of 27% demonstrates a sustained ability to scale in India's underpenetrated health insurance market
- The company is virtually debt-free with a debt-to-equity ratio of just 0.06, providing financial flexibility and low balance-sheet risk
- 5-year compounded profit growth of 20% indicates the business has been able to translate top-line expansion into bottom-line gains over a meaningful period
- Median sales growth of 21% over the last 10 years reflects consistent revenue compounding rather than lumpy or one-off growth
- The stock is trading roughly 9% below its 52-week high of ₹624.90, having recovered significantly from its 52-week low of ₹416.55 — a 36.5% move off the bottom
- 1-year stock CAGR of 12% shows the market has begun to re-rate the company following the earnings upturn
- 3-year compounded profit growth is negative at -3%, indicating the recent earnings surge follows a period of profit contraction
- Despite reporting consistent profits, the company pays zero dividend (yield 0%), offering no income return to shareholders
- P/B ratio of 3.21x is elevated for a company generating an ROE of just 7.35%, implying the stock price embeds expectations well above current return on capital
- 3-year ROE averages only about 10% and the latest annual ROE stands at 7.35%, which is modest relative to the valuation premium
- ROCE is reported at -9.4%, raising questions about the efficiency of total capital employed in the business
- 3-year stock CAGR of 0% means investors who bought three years ago have earned no capital appreciation, despite the business growing sales at 14% CAGR over the same period
- TTM sales growth of 14% represents a deceleration from the 5-year compounded sales growth of 29%, suggesting the top-line momentum may be slowing
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Star Health is delivering strong earnings momentum with Q2FY27 PAT up 233% YoY and a healthy combined ratio of 91.97%, while attracting institutional interest via HDFC MF's approved stake increase to 9.99%. The ₹2 crore IRDAI penalty is a minor regulatory blemish with no material operational impact. The trend is improving on profitability and institutional ownership, and sustained underwriting discipline will be key to watch in upcoming quarters.
- IRDAI penalty for claim violations Nov 20
IRDAI imposed a ₹2 crore penalty on Star Health for claim settlement violations identified during an early 2022 inspection. The company states no operational impact beyond the monetary fine.
- Q2FY27 PAT surges 233% YoY Oct 27
Star Health reported ₹26,481 lakh net profit for Q2FY27, up 233% YoY. Insurance revenue rose 15.4% to ₹507 crore and combined operating ratio improved to 91.97%.
- HDFC MF approved for 9.99% stake Nov 9
IRDAI approved HDFC Mutual Fund's acquisition of up to 9.99% equity in Star Health, including its existing 4.49% holding. Institutional interest signals confidence in the insurer.
- Promoter group reclassification sought Oct 30
Star Health applied to exchanges to reclassify promoter group entities as public shareholders under SEBI LODR Regulation 31A(8)(c).
- Analyst and investor meets scheduled Nov 11
Star Health scheduled one-on-one analyst meetings on Nov 3 covering Q2 FY27 performance, and a group analyst meet on Nov 16 at an annual investor conference in Mumbai.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,461 | 3,578 | 3,688 | 3,816 | 4,058 | 4,146 | 4,081 | 4,880 | 4,561 | 4,566 | 4,648 | 5,500 | 5,341 |
| Expenses | 3,296 | 3,191 | 3,502 | 3,391 | 3,912 | 3,861 | 4,089 | 4,292 | 4,448 | 4,395 | 4,500 | 4,751 | 4,984 |
| Operating Profit | 165 | 387 | 186 | 425 | 147 | 285 | −7 | 588 | 113 | 172 | 148 | 749 | 358 |
| OPM % | 4.8% | 11% | 5% | 11% | 3.6% | 7% | −0.2% | 12% | 2.5% | 3.8% | 3.2% | 14% | 7% |
| Other Income | 2 | 1 | 3 | 1 | 2 | 2 | 6 | 0 | −1 | 2 | 4 | −8 | −6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 167 | 388 | 190 | 426 | 149 | 287 | −1 | 588 | 112 | 173 | 151 | 742 | 352 |
| Tax % | 25% | 25% | 25% | 25% | 25% | 25% | −159% | 25% | 29% | 26% | 26% | 26% | 25% |
| Net Profit | 125 | 290 | 142 | 319 | 111 | 215 | 1 | 438 | 80 | 128 | 111 | 550 | 265 |
| EPS (₹) | 2.15 | 4.95 | 2.43 | 5.45 | 1.89 | 3.66 | 0.01 | 7.45 | 1.35 | 2.18 | 1.89 | 9.34 | 4.50 |
| YoY Sales growth | 15 | 16 | 18 | 16 | 17 | 16 | 11 | 28 | 12 | 10 | 14 | 13 | 17 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,069 | 1,595 | 2,012 | 2,888 | 3,775 | 4,987 | 5,050 | 10,602 | 12,096 | 14,021 | 16,101 | 17,825 | 20,056 |
| Expenses | 1,189 | 1,439 | 1,871 | 2,673 | 3,565 | 4,544 | 6,447 | 11,962 | 11,223 | 12,840 | 15,180 | 17,001 | 18,630 |
| Operating Profit | −120 | 156 | 141 | 215 | 210 | 443 | −1,397 | −1,360 | 873 | 1,182 | 921 | 824 | 1,426 |
| OPM % | −11% | 10% | 7% | 7% | 6% | 9% | −28% | −13% | 7% | 8% | 6% | 4.6% | 7% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | −3 | 7 | 5 | 6 | 12 | 9 | −8 |
| Interest | 1 | 2 | 3 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 19 | 18 | 20 | 23 | 28 | 29 | 46 | 43 | 52 | 59 | 71 | 79 | 0 |
| PBT | −140 | 137 | 118 | 171 | 182 | 413 | −1,446 | −1,397 | 826 | 1,129 | 861 | 754 | 1,418 |
| Tax % | 0% | 0% | 0% | 1% | 30% | 35% | −25% | −25% | 25% | 25% | 25% | 26% | — |
| Net Profit | −140 | 137 | 118 | 170 | 128 | 268 | −1,086 | −1,041 | 619 | 845 | 646 | 557 | 1,054 |
| EPS (₹) | −2.53 | 2.47 | 2.13 | 3.08 | 2.32 | 4.84 | −19.62 | −18.08 | 10.63 | 14.44 | 10.99 | 9.47 | 17.91 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
| Sales growth | — | 49 | 26 | 44 | 31 | 32 | 1 | 110 | 14 | 16 | 15 | 11 | 14 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 362 | 387 | 456 | 456 | 456 | 491 | 548 | 576 | 582 | 585 | 588 | 588 | 589 |
| Reserves | −220 | −27 | 334 | 504 | 773 | 1,153 | 2,947 | 4,045 | 4,862 | 5,799 | 6,471 | 6,987 | 9,847 |
| Borrowings | 0 | 0 | 0 | 250 | 250 | 250 | 250 | 720 | 470 | 470 | 470 | 470 | 76 |
| Other Liabilities | 954 | 1,012 | 1,423 | 2,138 | 3,394 | 4,233 | 6,756 | 8,174 | 9,313 | 10,914 | 13,255 | 16,019 | 13,781 |
| Total Liabilities | 1,096 | 1,372 | 2,213 | 3,347 | 4,872 | 6,127 | 10,501 | 13,514 | 15,226 | 17,768 | 20,785 | 24,064 | 24,293 |
| Fixed Assets | 46 | 62 | 77 | 92 | 85 | 90 | 183 | 113 | 217 | 159 | 357 | 404 | 312 |
| CWIP | 12 | 3 | 7 | 5 | 13 | 12 | 19 | 4 | 10 | 16 | 24 | 9 | 0 |
| Investments | 502 | 807 | 1,428 | 2,165 | 3,030 | 4,290 | 6,733 | 11,373 | 13,276 | 15,491 | 17,703 | 19,780 | 22,491 |
| Other Assets | 535 | 500 | 700 | 1,085 | 1,744 | 1,735 | 3,565 | 2,024 | 1,723 | 2,102 | 2,701 | 3,871 | 1,490 |
| Total Assets | 1,096 | 1,372 | 2,213 | 3,347 | 4,872 | 6,127 | 10,501 | 13,514 | 15,226 | 17,768 | 20,785 | 24,064 | 24,293 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | — | — | 321 | 557 | 776 | 647 | 890 | 56 | 1,276 | 1,310 | 1,379 | 1,873 |
| Investing | — | — | −497 | −663 | −731 | −1,006 | −2,418 | −3,786 | −1,097 | −1,177 | −1,151 | −1,067 |
| Financing | — | — | 310 | 249 | 333 | 122 | 2,613 | 2,509 | −268 | 23 | −4 | −31 |
| Net Cash Flow | — | — | 134 | 143 | 379 | −237 | 1,086 | −1,221 | −89 | 156 | 224 | 775 |
| Free Cash Flow | — | — | 283 | 521 | 746 | 614 | 844 | −7 | 1,229 | 1,187 | 1,297 | 1,797 |
| CFO/EBITDA | — | — | 228 | 260 | 397 | 168 | −70 | −4 | 145 | 119 | 170 | 250 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Conversion Cycle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Working Capital Days | −255 | −179 | −191 | −196 | −260 | −238 | −397 | −258 | −255 | −249 | −261 | −286 |
| ROCE % | — | 55% | 21% | 19% | 14% | 25% | −51% | −31% | 15% | 18% | 12% | 10% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Star Health Insurance insights
36 extracted metrics across FY15–FY27.
Documents
- Q2 FY27 concall · Oct 2026Transcript PPT Recording
- Concall · May 2026Transcript PPT Recording
- Concall · Apr 2026PPT
- Concall · Apr 2026PPT
- 28 Jan 2025
- 28 Sep 2026
- 2 Apr 2026
- 29 Sep 2025
- 4 Apr 2025
- 3 Oct 2024
- General announcements 18 Nov 2026
- General announcements 16 Nov 2026
- General announcements 16 Nov 2026
Frequently Asked Questions about Star Health Insurance
What does Star Health & Allied Insurance Company Ltd do?
Where is Star Health & Allied Insurance Company Ltd (STARHEALTH) listed?
Which sector does Star Health & Allied Insurance Company Ltd belong to?
What is the market capitalisation of Star Health & Allied Insurance Company Ltd?
What is the PE ratio of Star Health & Allied Insurance Company Ltd?
What is the 52-week high and low of Star Health & Allied Insurance Company Ltd?
What is the Return on Equity (ROE) of Star Health & Allied Insurance Company Ltd?
Company Information
Star Health & Allied Insurance Ltd (Star) is India’s first Standalone Health Insurance provider and is the largest private health insurer in India with a market share of 15.8% in the Indian health insurance market in FY21 with leadership in the attractive retail health segment.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/STARHEALTH.md for Star Health & Allied Insurance Company Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.